Idorsia’s sleep medicine is gaining ground in Europe, and the next big question is whether it can break out into new regions and make the business less dependent on a single product. A newer treatment for hard-to-control high blood pressure and a deal-making strategy could add a second growth engine, but delays in U.S. rule changes and tight funding could derail the story.Read more
A lot of the current excitement around Idorsia leans on its sleep drug and newer blood pressure treatment taking off quickly and winning broad access, but several key approvals and reimbursement decisions still need to fall into place. If uptake, pricing pressure, or funding needs disappoint, today’s optimism could cool even as the company pushes into more countries and signs new partners.Read more
Idorsia’s sleep drug is growing abroad and its high blood pressure treatment could open a much larger market, but both still hinge on heavy marketing, reimbursement, and the right partners to scale. The real swing factor is whether these launches gain wider doctor adoption fast enough to offset delays, competition, and the company’s limited time to reach sustainable profits.Read more
No trending discussion available.
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat psoriasis; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis. It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; and collaboration with Viatris Inc. to develop and commercialize selatogrel and cenerimod. Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
